HYBIO(SZ:300199)2022-12-06 08:20Company Overview - Shenzhen Hanyu Pharmaceutical Co., Ltd. was established in 2003, focusing on the research, production, and sales of peptide drugs, recognized as a national high-tech enterprise [2] - The company has established multiple subsidiaries and research centers, including a national peptide drug public laboratory and a production base for peptide drugs [2] Financial Performance - In the first three quarters of 2016, the raw material drug business achieved revenue of approximately CNY 110 million, a year-on-year increase of over 500% [3] - The peptide business generated nearly CNY 90 million in revenue, with a growth rate of about 8% [3] - The revenue from Terlipressin reached CNY 119,401,132.91, reflecting a year-on-year growth of 38.61% [4] Research and Development - Over 30% of the company's employees are involved in R&D, with R&D investment consistently exceeding 10% of sales revenue [3] - The company has applied for over 300 invention patents and has received nearly 200 authorized patents [3] - Hanyu Pharmaceutical has participated in several national-level major scientific projects and has been recognized with various awards for innovation and quality [3] Market Strategy - The company has secured exclusive agency rights for the non-invasive continuous glucose monitoring device GlucoPred in the Chinese market [2] - A strategic partnership with Tencent was established to enhance the management of chronic diseases through mobile internet technology [3] - The company aims to expand its international market presence, particularly in the raw material drug sector, leveraging its R&D and technical advantages [4]